Team-Based Deprescribing Program to Improve Health and Costs for Adults With Chronic Kidney Disease in Qatar A Randomized Trial
Led by Hamad Medical Corporation · Updated on 2025-10-01
424
Participants Needed
1
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Chronic Kidney Disease CKD is a major global health problem linked to cardiovascular issues, infections, cognitive decline, and increased death rates. In Qatar, about 13% of people have CKD, often facing challenges from taking many medications, which can reduce quality of life and cause negative health and financial effects. This research aims to create and test a multidisciplinary deprescribing program to manage medication use in CKD patients and improve their clinical and economic outcomes through a randomized controlled trial in Qatar.
The study involves developing a deprescribing team and program to carefully review and adjust medications for patients with advanced CKD experiencing inappropriate polypharmacy. Patients will be randomized to either receive usual care or a structured deprescribing intervention provided by a multidisciplinary team. The intervention includes medication review by pharmacists and nephrologists, medication plan adjustments, follow-up calls by specialist nurses, and coordination with primary care providers. The study is conducted in three phases preparation, intervention, and post-intervention economic assessment.
Participants will be monitored at baseline, 3 months, and 6 months for medication appropriateness, pill burden, quality of life, treatment burden, adherence, emergency visits, hospitalizations, adverse effects, and cost savings. Follow-up calls help identify withdrawal symptoms or concerns. The study evaluates the impact of deprescribing on health outcomes and healthcare costs over six months, aiming to support wider adoption of deprescribing programs in Qatars healthcare system.
CONDITIONS
Brief Title
Deprescribing Intervention for Patients With Chronic Kidney Disease
Research Team
A
Abdullah Hamad, MD
A
Ahmed Awaisu, Ph.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with end-stage renal disease receiving hemodialysis or followed at a low clearance clinic
Receiving treatment at an ambulatory kidney center in Qatar for at least two months
Able to communicate in Arabic and/or English
Aged 18 years or older
You will not qualify if you...
Unstable or has a psychiatric condition
Exhibits uncontrolled or exit-seeking behaviors such as confusion or frustration
Critically ill, pregnant, mentally ill, has dementia, or unconscious
Has a limited life expectancy of less than 6 months
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Intervention
Duration - 1 to 2 weeks
Participants in the intervention arm receive a structured deprescribing program by a multidisciplinary team including medication review, plan implementation, and monitoring during appointments and at discharge.
1 to 2 visits at the center during the intervention period
Follow-up
Duration - Approximately 1 month
Participants receive 3 post-appointment follow-up phone calls to monitor withdrawal symptoms or concerns on day 2, day 7, and day 28 after the intervention.
3 phone calls following intervention
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Optimizing Heart Failure and Chronic Kidney Disease Treatment in Elderly Patients Using Sodium Zirconium Cyclosilicate to Manage Potassium Levels
Long-Term Safety Follow-Up of Participants Previously Treated with Renal Autologous Cell Therapy for Chronic Kidney Disease
Safety Study of Oral Desidustat Over 52 Weeks for Treating Anemia in Adults with Chronic Kidney Disease
Comparing Empagliflozin and Dapagliflozin for Treatment of Type 2 Diabetes, Chronic Kidney Disease, and Heart Failure Using Cluster Randomization in Electronic Health Records
Impact of a 6-Month Home-Based Walking Program on Memory and Brain Health in Older Adults with Chronic Kidney Disease and Mild Cognitive Impairment
Effect of Oral Equol on Vascular Health in Postmenopausal Women With and Without Chronic Kidney Disease
A Randomized, Placebo-Controlled, Crossover Phase 2 Study
Study of Chronic Kidney and Cardiovascular Disease Progression in American Indians of the Southwestern US Using the CRIC Protocols
Study of Colchicine to Treat Heart Disease in Adults with Chronic Kidney Disease Ages 21 to 80
Study of APOL1 Genetic Testing to Understand Kidney Disease Risk and Patient Attitudes in African American Adults
Study Comparing Length of Dual Anti-Platelet Therapy Using Aspirin and Clopidogrel or Prasugrel After New Generation Drug-Eluting Stents in Adults with Advanced Chronic Kidney Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Medication-Related Burden among Patients with Chronic Disease Conditions: Perspectives of Patients Attending Non-Communicable Disease Clinics in a Primary Healthcare Setting in Qatar.
Amani Zidan, Ahmed Awaisu, Maguy Saffouh El-Hajj...